Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6334805 | 0.99 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL5807814 | 0.90 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL5808948 | 0.88 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL5811070 | 0.86 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL5810967 | 0.85 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL5806283 | 0.84 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL6333578 | 0.83 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL27609771 | 0.82 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL4436286 | 0.81 | PTGS2 (0.54) | CNR1CNR2 | |
| SCHEMBL5811601 | 0.81 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060190-A2 | IMIDAZOLE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060203-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DEMENTIA AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060199-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060202-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2005099705-A2 | PREPARATION OF IMIDAZOLE DERIVATIVES AND METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-27 | — | — | WO | claimed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-20080044353-A1 | Combination Therapy for Weight Management | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1729762-A4 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7253168-B2 | Substituted 1-benzyl-4-substituted piperazine analogues | NEUROGEN CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1809626-A2 | ARYL SUBSTITUTED 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS LIGANDS OF THE MELANIN CONCENTRATING HORMONE RECEPTOR | Neurogen Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1756107-A2 | ARYL-SUBSTITUTED PIPERAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006009789-A2 | ARYL-SUBSTITUTED PIPERAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | NEUROGEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2005110982-A2 | SUBSTITUTED 1-BENZYL-4-SUBSTITUTED PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110989-A1 | SUBSTITUTED 1-HETEROARYL-4-SUBSTITUTED PIPERAZINE AND PIPERIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050239791-A1 | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues | NEUROGEN CORPORATION | 2005-10-27 | — | — | US | disclosed |
| WO-2005094305-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044353-A1 | Combination Therapy for Weight Management | CNR1, CNR2, MCHR1 | CNR1 1/4885CNR2 2/4885 |
| US-20050239791-A1 | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues | MCHR1, MCHR2, PRLHR | CNR1 103/4885CNR2 168/4885 |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | MCHR1, MCHR2, PRLHR | CNR1 88/4885CNR2 163/4885 |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR1 405/4885CNR2 340/4885 |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | MCHR1, MCHR2, PRLHR | CNR1 104/4885CNR2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.